ReviewInternational journal of molecular sciences2022
Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Converting focused ultrasound-based boiling histotripsy into a systemic cancer vaccine using antigen-capturing microparticles.Theranostics · 2026Article
- Dendritic cell-based immunotherapy modulates the systemic inflammatory profile in a 4T1 breast cancer model.Exploration of targeted anti-tumor therapy · 2026Article
- The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy.Cell death & disease · 2025Review
- Oncolytic virus-mediated p53 activation boosts the antitumor immunity of a p53-transduced dendritic cell vaccine.NPJ vaccines · 2025Article
- UDP-glucose regulates dendritic cell mitochondrial respiration via a nitric oxide-dependent mechanism.Journal of leukocyte biology · 2025Article
- Potential Mechanisms for Immunotherapy Resistance in Adult Soft-Tissue Sarcoma.Targeted oncology · 2025Review
- Osteosarcoma biomarker analysis and drug targeting prediction based on pyroptosis-related genes.Medicine · 2025Article
- The roles of lncRNATranslational cancer research · 2024Article
- Article
- Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy.Journal of nanobiotechnology · 2023Article
- Review
- Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells.Cancer research · 2023Article
- Dendritic Cell and Cancer Therapy.International journal of molecular sciences · 2023Article
- Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Dendritic cells mediate innate and adaptive immune responses and are directly involved in the activation of cytotoxic T lymphocytes that kill tumor cells. Dendritic cell-based cancer immunotherapy has clinical benefits. Dendritic cell subsets are diverse, and tumors can be hot or cold, depending on their immunogenicity; this heterogeneity affects the success of dendritic cell-based immunotherapy. Here, we review the ontogeny of dendritic cells and dendritic cell subsets. We also review the characteristics of hot and cold tumors and briefly introduce therapeutic trials related to hot and cold tumors. Lastly, we discuss dendritic cell-based cancer immunotherapy in hot and cold tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.